High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT) remains a critical treatment modality for lymphoma. While anthracycline-based regimens are foundational in lymphoma therapy, their cardiotoxicity often precludes use in auto-HSCT. Our prior research established the tolerability and survival benefits of mitoxantrone-based conditioning regimen over BEAM in lymphoma patients undergoing auto-HSCT. Although liposomal mitoxantrone is hypothesized to exhibit reduced cardiotoxicity, comparative studies evaluating its safety and efficacy in auto-HSCT settings are scarce.

We initially compared cardiotoxicity biomarkers (CK-MB, LDH) and cardiomyocyte pathology in pre-clinical study, treated with mitoxantrone versus liposomal mitoxantrone in mice at human HSCT-equivalent doses. Liposomal mitoxantrone demonstrated significantly reduced cardiotoxicity. Subsequently, we conducted a prospective clinical trial (ChiCTR2500099269) from July 2022 to July 2025, comparing cardiotoxicity and efficacy between mitoxantrone (60 mg/m², n=29) and liposomal mitoxantrone (60 mg/m², n=28) as conditioning regimens for auto-HSCT. Patients underwent comprehensive assessment at baseline and 4 weeks post-chemotherapy using 3D echocardiography-derived myocardial work indices and biomarkers (Troponin T, CK-MB, BNP, LDH) to predict chemotherapy-related cardiotoxicity.The liposomal mitoxantrone group exhibited significantly lower cardiotoxicity biomarker fluctuation. Logistic regression analysis identified GLS decrease> 10%, LDH, TnT elevated after auto-HSCT as the strongest independent predictors of chemotherapy-induced cardiotoxicity. Both regimens demonstrated comparable efficacy in auto-HSCT. Three patients in the mitoxantrone group developed heart failure or severe atrial fibrillation after HSCT, whereas no events occurred in the liposomal group. Liposomal mitoxantrone shows promising potential for auto-HSCT conditioning. Myocardial work indices and specific biomarkers GLS could be integrated into clinical protocols for early detection and intervention of cardiovascular complications during chemotherapy.

This content is only available as a PDF.
2025
Sign in via your Institution